Sheridan said no significant differences in any of the efficacy end points were seen, which “was expected given the active control, small sample size, and exploratory phase 2 nature of this study.” Oct 28 news release about outpatient studyhttp://investor.shareholder.com/biocryst/ReleaseDetail.cfm?ReleaseID=343466 In the other trial, hospital patients who were seriously ill with flu were treated for 5 days with either IV peramivir or oseltamivir, with similar results in both groups, including no deaths and a median of 4.0 days to hospital discharge, the company said. Oct 27 news release about hospital studyhttp://investor.shareholder.com/biocryst/ReleaseDetail.cfm?ReleaseID=343132 Clinical stability was a composite measure based on temperature, oxygen saturation, respiratory rate, systolic blood pressure, and heart rate. For ethical reasons, the study included no placebo arm. In addition, both peramivir groups had significant improvements in a composite symptoms score, starting as early as 24 hours after treatment, the statement said. The drug was well-tolerated, with adverse-event profiles similar for the treatment and placebo groups. Hospital studyThe inpatient study was designed primarily to assess how long it would take patients with serious or life-threatening flu to become clinically stable with 5 days of treatment with peramivir or oseltamivir. The study was conducted at centers in the United States, Canada, Hong Kong, Singapore, Australia, New Zealand, and South Africa. “This phase 2 study was a critical test of peramivir, which demonstrated for the first time that a single administration of this potent neuraminidase inhibitor can be effective in treating seasonal influenza,” Dr. William P. Sheridan, chief medical officer of BioCryst, said in the news release. Secondary outcomes for all groups included no mortality, no clinical relapse, a median of 4.0 days to hospital discharge, and a median of 10.8 days to resumption of normal activities, the company reported. Sep 20, 2007, CIDRAP News story “Trial of injectable flu drug yields disappointing results” Sheridan also said that the zero mortality in the study is “an important finding worthy of follow-up,” given that a previous epidemiologic study showed a mortality rate of 10% in 219 patients who were not treated with neuraminidase inhibitors. See also: Page with link to recording of Oct 27 BioCryst teleconference (free registration required)http://investor.shareholder.com/biocryst/eventdetail.cfm?eventid=60565 Peramivir is a neuraminidase inhibitor, like the licensed antivirals oseltamivir (Tamiflu), which is taken orally, and zanamivir (Relenza), inhaled as a powder. In response to questions, he said the study was not designed to show differences between peramivir and oseltamivir. He said peramivir is important because it permits parenteral treatment of flu patients, adding, “At the ICAAC meeting the need for a parenteral drug for influenza has come up several times already. Also there’s concern about resistance to existing drugs, including oseltamivir.” The primary end point was time to alleviation of symptoms, which was 81.8 hours for the placebo group. The respective times for the 300-mg and 600-mg peramivir groups were 59.1 and 59.9 hours, both of which were significant reductions, the company said. Oct 31, 2008 (CIDRAP News) BioCryst Pharmaceuticals Inc. reported encouraging results this week in two phase 2 trials of its injectable antiviral drug, peramivir, a potential new treatment for influenza. In one study, a single intravenous (IV) dose of peramivir in outpatients ill with flu reduced the duration of their symptoms by about 22 hours compared with a placebo group, a statistically significant difference, according to BioCryst, based in Birmingham, Ala. Neither set of results has yet been published in a peer-reviewed journal. The company described the inpatient study in a press release and a teleconference on Oct 27; the outpatient study was reported in an Oct 28 press release and a poster presentation at the 46th Interscience Conference on Antimicrobials and Chemotherapy/Infectious Diseases Society of America (ICAAC/IDSA) meeting this week in Washington, DC. Outpatient findingsThe outpatient study was sponsored and conducted in Japan by Shionogi & Co. Ltd., which in 2007 bought from BioCryst the rights to develop and market peramivir in Japan. “The time to clinical stability was 25.3 hours for all groups combined, with no statistically significant differences across treatment groups,” Sheridan reported during the Oct 27 conference call (a recording of which is available online). In the news release, Dr. Michael Ison of Northwestern University, principal investigator in the study, said, “This landmark study provides us great insight into the course of treatment for patients who are hospitalized for influenza. The results indicate a potential role for antiviral therapy, which is critical as currently there are no antivirals approved for patients hospitalized for acute serious or potentially life-threatening influenza.” The new findings come 13 months after the company reported disappointing results in an earlier phase 2 trial of the drug. In that study, flu patients who received injections of peramivir did better than a placebo group, but the difference was not significant. The company said at the time that the use of shorter needles than were used in an earlier trial probably resulted in inadequate doses. The study involved 296 patients who tested positive for influenza within 48 hours after symptom onset, BioCryst reported. The volunteers were divided into three groups, with 99 receiving 300 milligrams (mg) of peramivir IV, 97 receiving 600 mg of the drug IV, and 100 receiving an IV placebo. The investigators enrolled 122 patients who had flu confirmed by polymerase chain reaction. Of these, 41 received 75 mg of oseltamivir twice daily, 41 received 200 mg of IV peramivir twice daily, and 40 received 400 mg of IV peramivir twice daily.
New Delhi: The International Cricket Council on Saturday (September 29) released the revised version of the controversial Duckworth-Lewis-Stern (DLS) along with the updated ICC Playing Conditions and ICC Code of Conduct, that will come into effect from September 30, when South Africa lock horns with Zimbabwe in the first One-Day International (ODI) of their series, which will be played in Kimberley.REVISED Duckworth-Lewis-Stern (DLS)This is the second update for the third version of the DLS System since its inauguration in 2014.The DLS has been put into play alongside ball-by-ball analysis of scoring, including the powerplays that have been played during the previous four years. So, that means the current revision is based on the 700 ODIs and 428 T20Is.The latest update has stated that the teams speed up their scoring towards the end of an innings and the average scores have shot up in the ODIs.The updated version of the DLS have revised the scoring patterns between ODI (final 20 overs) and T20 matches in both men and women’s cricket matches.ALSO READ: Did Cristiano Ronaldo rape American model in Las Vegas?ICC CODE OF CONDUCTMeanwhile, some new charges and change in the level of existing offenses have been introduced and revised in the ICC Code of Conduct for Players and Staffs, which will also come into play from September 30.Attempting to gain and unfair advantage (cheating, other than ball-tampering (New offence) – Level 2 and 3Personal Abuse (New Offence) – Level 2 and 3Audible obscenity (New Offence) – Level 1Disobeying an umpire’s instructions (New offence) – Level 1Changing the condition of the ball – Revised to level 3 from level.Match referees are now bound to hear the Level 1, 2 and 3 charged with Judicial Commissioner getting the responsibility of Level 4 charges and appeals.The maximum sanction for a Level 3 offence has been increased from eight suspension points to 12 suspension points (equivalent to 6 Test matches or 12 ODIs). Whereas, Match referees will now hear Level 1, 2 and 3 charges with a Judicial Commissioner only hearing Level 4 charges and appeals. For all the Latest Sports News News, Cricket News News, Download News Nation Android and iOS Mobile Apps.
Published on June 2, 2016 at 10:00 pm Contact Tomer: email@example.com | @tomer_langer Facebook Twitter Google+ Syracuse attack Kayla Treanor did not win the Tewaaraton Award Thursday night, marking the third year in a row she was named one of the five finalists, but didn’t win the award. Instead, Maryland’s Taylor Cummings took home college lacrosse’s top individual honor for a record-setting third year in a row.It was a record-setting year individually for Treanor. Her 217 draw controls set the single-season NCAA record and her 50 goals gave her 260 for her career, most in program history. She also finished her illustrious career with 393 points, which is second most in SU history and fourth most in NCAA history.The Orange’s season, and Treanor’s career, ended on May 27 in the semifinals of the NCAA tournament against Maryland in a blowout 19-9 loss in Chester, Pennsylvania.“Kayla Treanor is amazing … the greatest Syracuse lacrosse player ever,” Syracuse head coach Gary Gait said after the game. “If she’s not the most amazing player … for a single player to make that much of a difference is amazing.” Comments AdvertisementThis is placeholder text
Football club ‘Vitez’ has managed to qualify to BIH Premier League by becoming the first team of the First League of FBiH and now they are planning to acquire new players, reports sportsport.baTheir newest addition to the team is Marko Mišić, who used to play for Olimpic from Sarajevo.This 20 year old midfielder left Olimpic because he was not satisfied with the number of minutes he spent playing and now he’s moving to Vitez.Mišić added that he hopes Vitez will play well in the Premier League and that it will achieve good results.